Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

N.Korea says COVID-19 vaccines are 'no panacea', warns of lengthy battle

Published 05/05/2021, 08:58 AM
Updated 05/05/2021, 09:27 AM
© Reuters. FILE PHOTO: People wearing protective face masks commute amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea March 30, 2020, in this photo released by Kyodo. Picture taken March 30, 2020. Mandatory credit Kyodo/via REUTERS

By Hyonhee Shin

SEOUL (Reuters) -North Korea's state media warned of the prospect of a lengthy battle against the coronavirus and said vaccines developed by global drugmakers were proving to be "no universal panacea".

The country has not officially confirmed any infections, although South Korean officials have said an outbreak there cannot be ruled out, as the North had trade and people-to-people links with China before shutting its border early last year.

The Rodong Sinmun, the official newspaper of North Korea's ruling Workers' Party, said on Tuesday the global pandemic was only worsening, despite the development of vaccines.

"Novel coronavirus vaccines introduced competitively by various countries were once regarded as a glimmer of hope for humanity that could end the fight against this frightening disease," Rodong Sinmun said.

"But the situations in many countries are clearly proving that the vaccines are never a universal panacea," it said, citing news reports of rising numbers of new cases overseas and safety concerns surrounding some vaccines.

It urged people to brace for a protracted pandemic, describing it as an "inevitable reality" that called for efforts to toughen anti-virus measures and foster loyalty to leader Kim Jong Un and his party.

North Korea was expected to receive nearly two million doses of AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine by the first half of this year, via the global COVAX sharing programme.

But last month Edwin Salvador, the World Health Organization (WHO) representative for North Korea, said the shipment was delayed due to supply shortages, citing the GAVI alliance, according to South Korean media.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

In a comment to Reuters, Salvador said North Korea was completing technical requirements to receive the vaccines, but did not elaborate.

The GAVI alliance, which co-leads COVAX with the WHO, told Reuters that shipments have not been made to North Korea due to its lack of "technical preparedness" and global supply shortages but could be expected later this year.

"(North Korea) remains eligible for COVAX support. Depending on the supply situation, a COVID-19 vaccine introduction could be envisaged in the second half of 2021," a GAVI official said, adding that concrete dates cannot be defined at this point.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.